Data supports fast approval for Roche's breast cancer drug: FDA staff

(Reuters) - Trial data on Swiss drugmaker Roche's breast cancer treatment Perjeta supported a faster approval of the drug for use in early stages of the disease, reviewers for the U.S. Food and Drug Administration said on Tuesday.

Source: http://feeds.reuters.com/~r/reuters/healthNews/~3/gm7B6Tb8q6U/story01.htm

phlebotomy training in pa phlebotomy courses in maryland online classes for phlebotomy